200 related articles for article (PubMed ID: 16939945)
1. New challenges and opportunities in managing substance abuse in Malaysia.
Mazlan M; Schottenfeld RS; Chawarski MC
Drug Alcohol Rev; 2006 Sep; 25(5):473-8. PubMed ID: 16939945
[TBL] [Abstract][Full Text] [Related]
2. Opiate addiction in China: current situation and treatments.
Tang YL; Zhao D; Zhao C; Cubells JF
Addiction; 2006 May; 101(5):657-65. PubMed ID: 16669899
[TBL] [Abstract][Full Text] [Related]
3. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
4. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
Ngo HT; Tait RJ; Hulse GK
Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
[TBL] [Abstract][Full Text] [Related]
5. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.
Chawarski MC; Mazlan M; Schottenfeld RS
Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145
[TBL] [Abstract][Full Text] [Related]
6. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.
Sullivan LE; Metzger DS; Fudala PJ; Fiellin DA
Addiction; 2005 Feb; 100(2):150-8. PubMed ID: 15679744
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients.
Wittchen HU; Apelt SM; Soyka M; Gastpar M; Backmund M; Gölz J; Kraus MR; Tretter F; Schäfer M; Siegert J; Scherbaum N; Rehm J; Bühringer G
Drug Alcohol Depend; 2008 Jun; 95(3):245-57. PubMed ID: 18337025
[TBL] [Abstract][Full Text] [Related]
8. Malaysia and harm reduction: the challenges and responses.
Reid G; Kamarulzaman A; Sran SK
Int J Drug Policy; 2007 Mar; 18(2):136-40. PubMed ID: 17689356
[TBL] [Abstract][Full Text] [Related]
9. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
Vicknasingam B; Mazlan M; Schottenfeld RS; Chawarski MC
Drug Alcohol Depend; 2010 Sep; 111(1-2):44-9. PubMed ID: 20478668
[TBL] [Abstract][Full Text] [Related]
10. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.
Maremmani I; Pani PP; Pacini M; Perugi G
J Subst Abuse Treat; 2007 Jul; 33(1):91-8. PubMed ID: 17588494
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
Koch AL; Arfken CL; Schuster CR
Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence.
Sullivan LE; Fiellin DA
Clin Infect Dis; 2005 Sep; 41(6):891-6. PubMed ID: 16107991
[TBL] [Abstract][Full Text] [Related]
13. Drug substitution therapy: a new approach in preventing the spread of HIV/AIDS in Malaysia.
Razali SM
Trop Doct; 2008 Apr; 38(2):109-10. PubMed ID: 18453507
[TBL] [Abstract][Full Text] [Related]
14. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence.
Lavie E; Fatséas M; Denis C; Auriacombe M
Drug Alcohol Depend; 2009 Jan; 99(1-3):338-44. PubMed ID: 18824311
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy.
Messinis L; Lyros E; Andrian V; Katsakiori P; Panagis G; Georgiou V; Papathanasopoulos P
Hum Psychopharmacol; 2009 Oct; 24(7):524-31. PubMed ID: 19650155
[TBL] [Abstract][Full Text] [Related]
16. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.
Raffa JD; Grebely J; Tossonian H; Wong T; Viljoen M; Khara M; Mead A; McLean M; Duncan F; Petkau AJ; DeVlaming S; Conway B
Drug Alcohol Depend; 2007 Jul; 89(2-3):306-9. PubMed ID: 17383117
[TBL] [Abstract][Full Text] [Related]
17. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.
Banta-Green CJ; Maynard C; Koepsell TD; Wells EA; Donovan DM
Addiction; 2009 May; 104(5):775-83. PubMed ID: 19344438
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of mental and physical health disorders among older methadone patients.
Rosen D; Smith ML; Reynolds CF
Am J Geriatr Psychiatry; 2008 Jun; 16(6):488-97. PubMed ID: 18515693
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus prevention and the potential of drug abuse treatment.
Metzger DS; Navaline H
Clin Infect Dis; 2003 Dec; 37 Suppl 5():S451-6. PubMed ID: 14648463
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine use: the international experience.
Carrieri MP; Amass L; Lucas GM; Vlahov D; Wodak A; Woody GE
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S197-215. PubMed ID: 17109307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
